Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants
The new abstract was presented by authors at the
Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant,
Navin FernandoMD, Ann Chancellor CCRC, Paul MannerMD, University of Washington, Seattle, WA, 2021 Proceedings of Orthopaedic Research Society, Paper 0980
The retrospective review was performed at a single medical institution between 2016 and 2019 using a financial database and electronic health records.
Patient demographics, total direct costs, length of stay (LOS) and opioid use were all investigated. Two groups were evaluated for procedures performed by a single surgeon, Dr.
- Primary group – patient-specific implant (
- Comparison group – traditional implant (Zimmer Persona®)
- Control group – traditional implant (Stryker Triathlon®) performed by second surgeon
"We've been very pleased with the early outcomes for patients with the
“It is very gratifying to see
The median patient age was 66 years old, and the median BMI was 31 for the three groups.
Mean LOS analysis:
- 1.35 days for
- 1.99 days for Zimmer Persona® patients
- 1.83 for Stryker Triathlon® patients
Total direct costs analysis:
$9,341for ConformisiTotal® patients (savings of $1,006to $1,263per patient) $10,347for Zimmer Persona® patients $10,604for Stryker Triathlon® patients
There was no apparent difference in morphine equivalent dose use amongst the three groups.
The study concludes that total direct costs for hospital admissions appear to be more cost-effective with the
Three other comparative studies published between 2017 and 2019 also demonstrate that
- O’Connor, Mary, and Blau, Brittany, “Assessing the Economic Value of Custom Implants."
American Health & Drug Benefits. 2019, Vol.12, No. 2. Richard G. Buch, M.D., Robert W. Eberle, Jason Davis, M.D., and Rylie Buch, MS, “Does Implant Design Affect Hospital Metrics and Patents Outcomes? TKA Utilizing a ‘Fast-Track’ Protocol.” Reconstructive Review. 2019, Vol. 9 No. 1.
- Culler et al., “Comparison of Adverse Event Rates and Hospital Costs Between Customized Individually Made Implants and Standard Off-the-Shelf Implants for Total Knee Arthroplasty.” Arthroplasty Today 2017.
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
CONTACT: Investor Contact email@example.com +1 (781) 374-5598